Late pulmonary impairment following allogeneic bone marrow transplantation

Eur J Med Res. 1996 Apr 18;1(7):343-8.


The pulmonary function of 88 consecutive leukemic patients who had undergone allogeneic bone marrow transplantation (BMT) was studied beforehand, at 3 months, at 6 months, and annually thereafter until 5 years after grafting. The parameters for function which are indicative for obstructive and restrictive lung disease deteriorated in all patient groups during the first 3 to 6 months after BMT but partially recovered within one year. Long-term decline in lung function was similar in all patient groups, and neither the onset nor the magnitude of pulmonary dysfunction was related to the occurrence of pulmonary impairment within 6 months after grafting. Multivariate analysis was then employed to assess predictors for long-term pulmonary disease. Despite the obvious effect of chronic graft versus host disease on the course of lung function, it was in itself not a significant predictor of long-term pulmonary outcome. Rather, the conditioning regimen turned out to be indicative; compared with busulfan, fractionated total body irradiation was demonstrated to be clearly superior with a lower incidence of both restrictive and obstructive long-term lung impairment. Our data indicate a previously unknown long-term side effect of busulfan conditioning.

MeSH terms

  • Adult
  • Bone Marrow Transplantation / adverse effects*
  • Bone Marrow Transplantation / immunology
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease / prevention & control
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Leukemia, Myeloid, Acute / therapy
  • Lung Diseases / diagnosis
  • Lung Diseases / epidemiology
  • Lung Diseases / etiology*
  • Lung Diseases, Obstructive / diagnosis
  • Lung Diseases, Obstructive / epidemiology
  • Lung Diseases, Obstructive / etiology*
  • Male
  • Multivariate Analysis
  • Postoperative Complications*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Respiratory Function Tests
  • Time Factors
  • Transplantation, Homologous


  • Immunosuppressive Agents